Effect of Nigella sativa and its bioactive compound on type 2 epithelial to mesenchymal transition: a systematic review.
Epithelial
Fibrosis
Mesenchymal
Nigella sativa
Thymoquinone
Wound healing
Journal
BMC complementary and alternative medicine
ISSN: 1472-6882
Titre abrégé: BMC Complement Altern Med
Pays: England
ID NLM: 101088661
Informations de publication
Date de publication:
30 Oct 2019
30 Oct 2019
Historique:
received:
26
03
2019
accepted:
09
10
2019
entrez:
1
11
2019
pubmed:
2
11
2019
medline:
2
1
2020
Statut:
epublish
Résumé
Nigella sativa or commonly known as black seed or black cumin is one of the most ubiquitous complementary medicine. Epithelial to mesenchymal transition (EMT) of type 2 is defined by the balance between wound healing and tissue fibrosis, which is dependent to the state of inflammation. This systematic review is conducted to provide an overview regarding the reported effect of Nigella sativa and its bioactive compound on the type 2 EMT. A search was done in EBSCOHOST, OVID and SCOPUS database to obtain potentially relevant articles that were published between 1823 and August 2019. This review includes studies that focus on the effect of Nigella sativa and its bioactive compound on the events related to type 2 EMT. A total of 1393 research articles were found to be potentially related to the effect of Nigella sativa and its bioactive compound, thymoquinone on Type 2 EMT. After screening was done, 22 research articles met inclusion criteria and were included in this review. Majority of the studies, reported better wound healing rate or significant prevention of tissue inflammation and organ fibrosis following Nigella sativa or thymoquinone treatments. In terms of wound healing, studies included reported progression of EMT related pathological changes after treatment with Nigella sativa or thymoquinone. Alternatively, in terms of fibrosis and inflammation, studies included reported reversal of pathological changes related to EMT after treatment with Nigella sativa or thymoquinone. Through this review, Nigella sativa and thymoquinone have been associated with events in Type 2 EMT. They have been shown to promote wound healing, attenuate tissue inflammation, and prevent organ fibrosis via regulation of the EMT process.
Sections du résumé
BACKGROUND
BACKGROUND
Nigella sativa or commonly known as black seed or black cumin is one of the most ubiquitous complementary medicine. Epithelial to mesenchymal transition (EMT) of type 2 is defined by the balance between wound healing and tissue fibrosis, which is dependent to the state of inflammation. This systematic review is conducted to provide an overview regarding the reported effect of Nigella sativa and its bioactive compound on the type 2 EMT.
METHODS
METHODS
A search was done in EBSCOHOST, OVID and SCOPUS database to obtain potentially relevant articles that were published between 1823 and August 2019. This review includes studies that focus on the effect of Nigella sativa and its bioactive compound on the events related to type 2 EMT.
RESULTS
RESULTS
A total of 1393 research articles were found to be potentially related to the effect of Nigella sativa and its bioactive compound, thymoquinone on Type 2 EMT. After screening was done, 22 research articles met inclusion criteria and were included in this review. Majority of the studies, reported better wound healing rate or significant prevention of tissue inflammation and organ fibrosis following Nigella sativa or thymoquinone treatments. In terms of wound healing, studies included reported progression of EMT related pathological changes after treatment with Nigella sativa or thymoquinone. Alternatively, in terms of fibrosis and inflammation, studies included reported reversal of pathological changes related to EMT after treatment with Nigella sativa or thymoquinone.
CONCLUSION
CONCLUSIONS
Through this review, Nigella sativa and thymoquinone have been associated with events in Type 2 EMT. They have been shown to promote wound healing, attenuate tissue inflammation, and prevent organ fibrosis via regulation of the EMT process.
Identifiants
pubmed: 31666058
doi: 10.1186/s12906-019-2706-2
pii: 10.1186/s12906-019-2706-2
pmc: PMC6821016
doi:
Substances chimiques
Benzoquinones
0
Plant Extracts
0
thymoquinone
O60IE26NUF
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
290Subventions
Organisme : Universiti Kebangsaan Malaysia
ID : FF-2017-020
Organisme : AMRUS Medik Sdn Bhd
ID : FF-2017-020
Références
Eur Rev Med Pharmacol Sci. 2016 Jun;20(12):2680-8
pubmed: 27383323
Nat Rev Cancer. 2007 Jun;7(6):415-28
pubmed: 17508028
J Int Adv Otol. 2018 Aug;14(2):285-289
pubmed: 29283096
Environ Toxicol Pharmacol. 2016 Jul;45:340-5
pubmed: 27375216
J Food Sci Technol. 2010 Dec;47(6):598-605
pubmed: 23572692
RSC Adv. 2018 Apr 18;8(26):14633-14639
pubmed: 35540763
Oncotarget. 2015 Aug 14;6(23):19580-91
pubmed: 26023736
J Pathol. 2013 Jan;229(2):141-4
pubmed: 23097196
J Clin Invest. 2003 Dec;112(12):1776-84
pubmed: 14679171
Development. 2012 Oct;139(19):3471-86
pubmed: 22949611
Redox Rep. 2016 Mar;21(2):50-60
pubmed: 26221999
Sci Transl Med. 2014 Dec 3;6(265):265sr6
pubmed: 25473038
Nat Cell Biol. 2009 Aug;11(8):943-50
pubmed: 19597490
Int Wound J. 2017 Feb;14(1):89-96
pubmed: 26688157
PLoS One. 2013 Jun 20;8(6):e66649
pubmed: 23818956
J Clin Invest. 2009 Jun;119(6):1438-49
pubmed: 19487820
Environ Toxicol. 2017 Feb;32(2):669-678
pubmed: 27060453
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Future Oncol. 2009 Oct;5(8):1145-68
pubmed: 19852727
J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):169-90
pubmed: 20467795
Int J Biol Macromol. 2017 Dec;105(Pt 1):1148-1160
pubmed: 28751051
Arch Immunol Ther Exp (Warsz). 2017 Apr;65(2):157-173
pubmed: 27393708
J Transl Med. 2016 Sep 29;14(1):281
pubmed: 27681697
Drug Des Devel Ther. 2018 May 22;12:1347-1352
pubmed: 29861626
Environ Sci Pollut Res Int. 2016 Dec;23(24):25356-25363
pubmed: 27696167
Biomed Pharmacother. 2017 Jun;90:626-637
pubmed: 28412654
J Biol Chem. 2007 Aug 10;282(32):23337-47
pubmed: 17562716
J Clin Invest. 2009 Jun;119(6):1429-37
pubmed: 19487819
J Cell Physiol. 2015 Mar;230(3):620-9
pubmed: 25164250
EMBO J. 2012 Jan 4;31(1):110-23
pubmed: 21983900
J Mammary Gland Biol Neoplasia. 2002 Oct;7(4):415-32
pubmed: 12882526
Int J Mol Sci. 2017 Jul 03;18(7):
pubmed: 28671607
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Hypertension. 2002 Feb;39(2):258-63
pubmed: 11847194
Am J Rhinol Allergy. 2011 Nov-Dec;25(6):e268-72
pubmed: 22185737
J Burn Care Res. 2013 Sep-Oct;34(5):e274-81
pubmed: 23816998
Mol Cell Biochem. 2013 Nov;383(1-2):243-51
pubmed: 23943306
Ultrastruct Pathol. 2014 Feb;38(1):26-33
pubmed: 24134725
Andrologia. 2018 Aug;50(6):e13014
pubmed: 29659036
J Cell Biol. 2006 Mar 27;172(7):973-81
pubmed: 16567498
J Mol Cell Cardiol. 2012 Jun;52(6):1213-25
pubmed: 22465037
Folia Morphol (Warsz). 2016;75(4):518-526
pubmed: 26916204
Toxicol Lett. 2016 Nov 16;262:80-91
pubmed: 27688165
J Cell Biol. 1995 Jul;130(2):393-405
pubmed: 7615639
J Pharmacopuncture. 2017 Sep;20(3):179-193
pubmed: 30087794
Carcinogenesis. 2008 Nov;29(11):2227-35
pubmed: 18725385
Int Immunopharmacol. 2016 Sep;38:70-80
pubmed: 27240137
Kidney Int. 2002 May;61(5):1714-28
pubmed: 11967021
Int J Physiol Pathophysiol Pharmacol. 2016 Dec 25;8(4):152-159
pubmed: 28078054
Pak J Pharm Sci. 2017 Jan;30(1):229-234
pubmed: 28603137
Dev Dyn. 2005 Jul;233(3):706-20
pubmed: 15937929